본문
SEOUL, Korea – L&C Bio, a leading regenerative medicine company specializing in human tissue, announced that Prof. Min Jung of Severance Hospital (Shinchon) presented the clinical results of MegaCarti®, a cartilage regeneration therapy, at two major international conferences in Australia:
-
AOA ASM 2023 (Australian Orthopaedic Association Annual Scientific Meeting), held in Melbourne from November 12–16, and
-
AKS ASM 2023 (Australian Knee Society Annual Scientific Meeting), held from November 16–19.
The AOA is Australia’s largest orthopedic professional body, with over 1,750 members. The AKS, a subspecialty group under the AOA, was founded in 1978 to advance the treatment and understanding of knee conditions. Both societies host Annual Scientific Meetings that attract global experts to exchange cutting-edge research and foster collaboration.
At these events, Prof. Jung delivered a presentation titled “Cartilage repair using particulated costal allocartilage”, which highlighted the clinical efficacy of MegaCarti® in treating moderate to severe degenerative osteoarthritis. His talk garnered significant attention from the international medical and academic community.
The clinical study enrolled 90 patients with ICRS Grade 3–4 cartilage defects. Participants were randomly assigned in a 1:1 ratio to receive either MegaCarti® with microfracture or microfracture alone. After 48 weeks, the MegaCarti® group showed a significantly higher MOCART score (56.0 ± 10.5) compared to the control group (43.0 ± 17.4), indicating better structural cartilage regeneration.
Additionally, at weeks 12, 24, and 48, the MegaCarti® group demonstrated statistically significant improvements in clinical outcomes, including VAS pain scores and KOOS (Knee injury and Osteoarthritis Outcome Score), compared to the control.
The results confirmed that combining MegaCarti® with microfracture surgery led to superior cartilage regeneration and functional recovery, with a favorable safety profile.
As of October, MegaCarti® is available for non-reimbursed use at major orthopedic and university hospitals in Korea, under the country’s new health technology assessment deferment program. L&C Bio actively supports treatment access through its official website, which lists eligible hospitals nationwide.
Recently, L&C Bio has been a key sponsor at major orthopedic symposia in Korea, including those hosted by the Korean Orthopaedic Association and the Korean Knee Society, where the company continues to showcase the therapeutic potential of MegaCarti® to domestic and international stakeholders.
